medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2018, Number 3

<< Back Next >>

Ann Hepatol 2018; 17 (3)

An Overview of Liver Transplant Pathology: Data from a Tertiary Referral Centre in Western India

Fonseca F, Kulkarni B, Hastak M, Kumaran V, Varma V, Kapoor S

Language: English
References: 40
Page: 426-436
PDF size: 432.66 Kb.


ABSTRACT

Introduction and aim. 1. Study of liver explants - Etiologic types of end-stage chronic liver disease (ESCLD) and acute liver failure (ALF) in adults and children. 2. Assessment of donor steatosis and incidental granulomas. 3. Post-transplant liver biopsies. Material and methods. Specimens of 180 explant hepatectomies, 173 donor wedge and 30 core liver biopsies, and 58 post transplant liver biopsies received in our department from April 2013 to March 2017. Results. 1. Most common causes of ESCLD in adults were: alcohol related (30.32%), hepatitis virus related (18.71%) and non-alcoholic steatohepatitis related (18.06%); and in children ≤ 12 years were: biliary atresia (27.27%), autoimmune disease (18.18%) and Wilson's disease (18.18%). Most common causes of ALF in adults and children were anti-tubercular therapy induced and idiopathic, respectively. 2. Prevalence rate of moderate steatosis (between 30-60%) was 4.28%. Incidental granulomas were seen in 5 cases. 3. Most common diagnoses of post-transplant biopsies in adults included acute cellular rejection (ACR) (36.17%), recurrence of viral disease (8.51%) and moderate non-specific portal triaditis (8.51%). Among children ≤ 12 years, most common diagnoses included unremarkable liver parenchyma, ACR and ischemia/reperfusion injury. Conclusion. 1. Alcohol- and hepatitis- virus related ESCLD, and biliary atresia are leading indications for liver transplantation in adults and children, respectively. 2. Prevalence of 4.28% of moderate steatosis, is much lower than that documented in western literature. Only 5 cases of incidental granulomas is unexpectedly low in a country endemic for tuberculosis. 3. Most common diagnoses of post-transplant liver biopsies in adults has been acute rejection, which is similar to the findings from much larger published series.


REFERENCES

  1. Child III CG, Turcotte JG. Surgery & portal hypertension. In: The liver and portal hypertension, Child III CG (Ed.). Saunders, Philadelphia; 1964, p. 50.

  2. Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, D'Amico G, et al. A model to predict survival in patients with end stage liver disease. Hepatology 2001; 33(2): 464-70.

  3. McDiarmid SV, Anand R, Lindblad AS. Principal investigators and institutions of the studies of Pediatric liver transplantation (SPLIT) Research group. Development of a pediatric end-stage liver disease score to predict poor outcome in children awaiting liver transplantation. Transplantation 2002; 74: 173-81.

  4. O'Grady J, Alexander G, Hayllar KM, Williams R. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology 1989; 97(2): 439-45.

  5. James Trotter. Selection of donors for living donor liver transplantation. Liv Transplant 2003; 9(Suppl. 2): S2-S7.

  6. Demetris AJ, Batts KP, Dhillon AP, Ferrell L, Fung J, Geller SA, Hart J, et al. Banff schema for grading liver allograft rejection: an international consensus document. Hepatology 1997; 25: 658-63.

  7. Strasberg SM, Howard TK, Molmenti EP, Herti M. Selecting the donor liver: risk factors for poor function after orthotopic liver transplantation. Hepatology 1994; 20(4, Pt. 1): 829-38.

  8. Nayak NC, Jain D, Vasdev N, Gulvani H, Saigal S, Soin A. Etiologic types of end-stage chronic liver disease in adults: analysis of prevalence and their temporal changes from a study on native liver explants. Eur J of Gastroenterol and Hepatol 2012; 24: 1199-208.

  9. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and Hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006; 45(4): 529-38.

  10. Da Villa G, Piccinino F, Scolastico C, Fusco M, Piccinino R, Sepe A. Long term epidemiological survey of Hepatitis B virus infection in a hyperendemic area (Afragola, southern Ita ly): results of a pilot vaccination project. Res Virol 1998; 149(5): 263-70.

  11. Ayata G, Gordon FD, Lewis WD, Pomfret E, Pomposelli JJ, Jenkins RL, Khettry U. Cryptogenic cirrhosis: clinicopathologic findings at and after liver transplantation. Hum Pathol 2002; 33(11): 1098-104.

  12. Daniel Dutra Romualdo da Silva, Rios Leite VH. Cirrhotic liver explants: regenerative nodule, dysplasia and hepatocellular carcinoma occurrence. J Bras Med Lab 2005: 41:437-42.

  13. Nayak NC. Hepatocellular carcinoma- a model of human cancer: clinicopathological features, etiology and pathogenesis. Indian J Pathol Microbiol 2003; 46: 1-16.

  14. Alter MJ. Epidemiology of hepatitis C virus infection. World J Gastroenterol 2007; 13: 2436-41.

  15. Phillipe Ichai, Didier Samuel. Etiology and prognosis of fulminant hepatitis in adults. Liver Transpl 2008; 14(Suppl. 2): S67-S69.

  16. Lee WM, Squires RH Jr, Nyberg SL, Doo E, Hoofnagle JH. Acute liver failure: summary of a workshop. Hepatology 2008; 47: 1401-15.

  17. Ichai P, Saliba F, Antoun F, Azoulay D, Sebagh M, Antonini TM, Escaut L, et al. Acute liver failure due to antitubercular therapy: Strategy for antitubercular treatment before and after liver transplantation. Liver Transpl 2010; 16: 1136-46.

  18. Mindikoglu AL, Magder LS, Regev A. Outcome of liver transplantation for drug-induced acute liver failure in the United States: analysis of the United Network for Organ Sharing database. Liver Transpl 2009; 15: 719-29.

  19. Harshad Devarbhavi. Antituberculous drug-induced liver injury: current perspective. Tropical Gastroenterology 2011; 32: 167-74.

  20. Kumar R, Shalimar, Bhatia V, Khanal S, Sreenivas V, Gupta SD, Panda SK, et al. Antituberculosis therapy-induced acute liver failure: magnitude, profile, prognosis, and predictors of outcome. Hepatology 2010; 51: 1665-74.

  21. Devarbhavi H, Dierkhising R, Kremers WK. Antituberculosis therapy drug-induced liver injury and acute liver failure. Hepatology 2010; 52: 798-9.

  22. Devarbhavi H, Dierkhising R, Kremers WK, Sandeep MS, Karanth D, Adarsh CK. Single-center experience with drug-induced liver injury from India: causes, outcome, prognosis, and predictors of mortality. Am J Gastroenterol 2010; 105: 2396-404.

  23. Balayan MS. Epidemiology of hepatitis E virus infection. J Viral Hepat 1997; 4: 155-65.

  24. Pinto RB, Schneider ACR, Silveira TR. Cirrhosis in children and adolescents: an overview. World J Hepatol 2015; 7: 392-405.

  25. Leonis MA, Balistreri WF. Evaluation and management of End-stage liver disease in children. Gastroenterology 2008; 134: 1741-51.

  26. Molleston JP, Sokol RJ, Karnsakul W, Miethke A, Horslen S, Magee JC, Romero R, et al. Evaluation of the child with suspected mitochondrial liver disease. J Pediatr Gastroenterol Nutr 2013; 57: 269-76.

  27. Squires RH Jr., Schneider BL, Bucuvalas J, Alonso E, Sokol RJ, Narkewicz MR, Dhawan A, et al. Acute liver failure in children: the first 348 patients in the pediatric acute liver failure study group. J Pediatr 2006; 148: 652-8.

  28. Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, Bales VS, Marks JS. Prevalence of obesity, diabetes and obesity-related health risk factors, 2001. JAMA 2003; 289(1): 76-9.

  29. Dare AJ, Phillips ARJ, Chu M, Hickey AJR, Bartlett A. Appraisal of donor steatosis in liver transplantation: a survey of current practice in Australia and New Zealand. Transplant Research and Risk Management 2102; 4: 31-7.

  30. Selzner M, Clavien PA. Fatty liver in liver transplantation and surgery. Semin Liver Dis 2001; 21(1): 105-13.

  31. Pungpagong S, Krishna M, Abraham SC, Keaveny AP, Dickson RC, Nakhleh RE. Clinicopathologic findings and outcomes of liver transplantation using grafts from donors with unrecognised and unusual diseases. Liv Transplant 2006; 12: 310-5.

  32. Geramidazeh B, Motevalli D, Nikeghbalian S, Seyed Ali Malek Hosseini. Histopathology of Post-transplant liver biopsies, the first report from Iran. Hepat Mon 2013; 13: e9389.

  33. Cong WM, Zhang SY, Wang ZL, Xue L, Liu YS, Zhang SH. Pathologic diagnosis of 1123 post-transplant liver biopsies from 665 transplant patients. Zhonghua Bing Li Xue Za Zhi 2005; 34: 716-9.

  34. Feray C, Samuel D, Thiers V, Gigou M, Pichon F, Bismuth A, Reynes M, et al. Reinfection of liver graft by hepatitis C virus after liver transplantation. Clin Invest 1992; 89(4): 1361-5.

  35. Arnold JC, Tox U, Goeser T, Otto G, Muller HM, Hofmann WJ, Stremmel W, et al. Recurrent hepatitis C virus infection after liver transplantation-long term follow-up with respect to the HCV genotypes/subtypes. Z Gastroenterol 1997; 35: 255-61.

  36. Rodriguez-Luna H, Vargas HE. Management of hepatitis C virus infection in the setting of liver transplantation. Liver transplantation 2005; 11: 479-89.

  37. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR cooperative study group. Hepatology 1996; 24: 289-93.

  38. Shih-Hsien Hsu, Ming-Lun Yeh, Shen-Nien Wang. New Insights in Recurrent HCV Infection after Liver Transplantation. Clinical and Developmental Immunology 2013. Article ID 890517.

  39. Shepherd RW, Turmelle Y, Nadler M, Lowell JA, Narkewicz MR, McDiarmid SV, Anand R, et al. Risk factors for rejection and infection in Pediatric liver transplantation. Am J Transplant 2008; 8: 396-403.

  40. Spada M, Riva S, Maggiori G, Cintorino D, Gridelli B. Pediatric liver transplantation. World J Gastroenterol 2009; 15: 648-74.




2020     |     www.medigraphic.com